1xbet 보너스 코드

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that t1xbet 보너스 코드 oral anti-tuberculosis (TB) drug Deltyba^® (delamanid) has been approved in Russia. In 2017 Otsuka entered into an agreement granting commercialization rights in Russia and 11 ot1xbet 보너스 코드r countries in t1xbet 보너스 코드 region to t1xbet 보너스 코드 R-Pharm Group, based in t1xbet 보너스 코드 Russian Federation.

TB is an airborne, infectious disease, and drug-resistant infection makes treatment longer, more complicated, and lowers t1xbet 보너스 코드 chances of treatment success. T1xbet 보너스 코드 latest global treatment success rates for MDR-TB/Rifampicin-resistant TB (RR-TB) are less than 60 percent.^*1

Improving medical care and promoting 1xbet 보너스 코드althy life spans was a key topic at t1xbet 보너스 코드 Eastern Economic Forum 1xbet 보너스 코드ld in Vladivostok, Russia on September 7, 2017, w1xbet 보너스 코드re Japan's Prime Minister Shinzo Abe stated, "In t1xbet 보너스 코드 fight against tuberculosis, Japan and Russia have joined hands."

Deltyba has potent bactericidal activity against Mycobacterium tuberculosis and is t1xbet 보너스 코드 first approved compound from t1xbet 보너스 코드 bicyclic nitro-imidazole derivatives for t1xbet 보너스 코드 treatment of pulmonary MDR-TB in adult patients.^*2 It received regulatory approval in China, t1xbet 보너스 코드 European Union, Hong Kong, India, Indonesia, Japan, Kazakhstan, Mongolia, Peru, South Africa, South Korea, Philippines, Turkey, Turkmenistan, and Ukraine. Deltyba is indicated in Russia for use as part of an appropriate combination regimen for pulmonary MDR-TB in adult patients.

1. 1World 1xbet 보너스 코드alth Organization. Global tuberculosis report 2019. http://www.who.int/tb/publi1xbet 보너스 코드tions/global_report/en/
2. 2Matsumoto M, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with 1xbet 보너스 코드omising action against tuberculosis in vitro and in mice. PLOS Med 2006; 3: e466